Semaglutide, the active ingredient in diabetes and weight-loss drugs Ozempic and Wegovy, may be linked to improved smoking cessation, a study published Monday suggests.
Compared to those who use Type 2 diabetes drugs like metformin and insulin, as well as glucagon-like peptide-1 (GLP-1) receptor agonists, semaglutide users had a lower chance of accessing health care for tobacco use disorders. They were also less likely to seek counseling and medication for smoking cessation.
